Table 4 Progression Free Survival after Third-line Treatment

Treatment

Rechallenge

128

5.82 (4.97–6.66)

.167

Regorafenib

266

4.01 (3.48–4.53)

Age, years

< 60

226

4.47 (3.85–5.09)

.555

≥ 60

165

4.57 (3.28–5.85)

Sex

Female

159

5.75 (4.59 – 6.91)

< .001

Male

219

4.11 (3.46 – 4.76)

ECOG PS

0/1

267

4.69 (3.95 – 5.44)

.133

2

51

3.94 (2.84–5.08)

Tumor side

Right colon

72

4.37 (3.47 – 5.27)

.925

Left colon

320

4.69 (4.04 – 5.35)

Metastases status^a

Synchronous

236

4.37 (3.56 – 5.09)

.031

Metachronous

157

4.79 (3.95 – 5.65)

Response to prior 2 lines

Disease control in both lines

256

4.86 (4.24–5.49)

< .001

Disease control in one line

123

4.01 (3.02–4.99)

Resistant to both lines

15

2.96 (2.75–3.16)